TrialsgrambetaRCTs are beautiful

POST-4

2021

Prevention of Syncope Trial 4

In 133 patients with recurrent vasovagal syncope and no serious comorbidity, midodrine reduced the proportion of patients with at least one syncope episode over 12 months compared with placebo.

Result

Efficacy: Proportion with ≥1 syncope episode over 12 monthsrelative risk 0.69 (95% CI 0.49-0.97) · P = 0.035

Below 1 favours midodrine, above 1 favours placebo.

Event rates
Absolute difference
19 points
NNT
6

Absolute difference and NNT are derived from the event rates.

Also reported: Absolute reduction 19 percentage points; NNT 5.3. Adverse effects similar in both arms.

Original publication
Subtopic
Vasovagal syncope
Design
Double-blind, placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Sheldon R, Faris P, Tang A, et al. Ann Intern Med. 2021;174(10):1349-1356.doi 10.7326/M20-5415

Discussion & critique

Small, short of its planned enrolment, followed for only 12 months and drawn largely from one centre, so the confidence interval brushes unity. Even so it is the only adequately powered placebo-controlled trial of midodrine and makes it the best-supported drug for young, healthy patients with a heavy syncope burden.